🏥 CEO Allen Guo describes it as a beacon of hope for patients. The facility will create over 110 jobs and support clinical development for gene therapies, enhancing New Jersey’s position in biomanufacturing. 🧪
Introduction:
This article discusses the opening of ProBio’s new state-of-the-art manufacturing facility in Hopewell, New Jersey, aimed at enhancing capabilities in the production of plasmid DNA and viral vectors for gene and cell therapies.
- ProBio, a subsidiary of GenScript Biotech, has inaugurated its 128,000-square-foot facility dedicated to cell and gene therapy at the Princeton West Innovation Campus.
- The facility is designed for good manufacturing practice (GMP) production of plasmid DNA and viral vectors, notably adeno-associated virus (AAV) and lentiviral vectors (LVV).
- ProBio’s CEO, Allen Guo, emphasized that this facility represents a significant step in supporting biopharmaceutical innovators and enhancing global healthcare solutions.
- The Hopewell site will create over 110 skilled jobs and is set to commence GMP AAV manufacturing by Q3 2025, with GMP LVV services following in early 2026.
- Industry leaders anticipate that this facility will strengthen New Jersey’s position in the biomanufacturing sector and expedite access to breakthrough therapies for patients.
Conclusion:
The establishment of ProBio’s new facility marks a pivotal development in the realm of cell and gene therapy manufacturing. By enhancing production capabilities and fostering local employment, ProBio positions itself as a key player in biotechnology, potentially accelerating the delivery of innovative treatments to patients in need.
